US2019133903A1PendingUtilityA1

Oral Compositions Containing Zinc, Stannous and Fluoride Ion Sources

Assignee: COLGATE PALMOLIVE COPriority: Jun 20, 2014Filed: Nov 2, 2018Published: May 9, 2019
Est. expiryJun 20, 2034(~7.9 yrs left)· nominal 20-yr term from priority
A61K 8/24A61Q 11/00A61K 8/365A61K 8/21A61K 8/19A61K 8/27
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An oral care composition containing a source of stannous ions, a source of fluoride ions and an insoluble source of zinc ions, such as zinc oxide. The composition contains an amount of citric acid sufficient to increase the level of soluble zinc ions.

Claims

exact text as granted — not AI-modified
1 . An oral care composition comprising in a single phase:
 (a) an orally acceptable vehicle;   (b) a source of fluoride ions;   (c) a source of stannous ions;   (d) an insoluble source of zinc ions;   (e) a buffering system comprising citric acid wherein the amount of citric acid is 0.5-4% by weight of the composition, and   wherein the composition has a total water content of less than 15% by weight, based on the weight of the composition.   
     
     
         2 - 5 . (canceled) 
     
     
         6 . The composition of  claim 1  wherein the insoluble source of zinc ions comprises a zinc salt of an organic acid. 
     
     
         7 . The composition of claim  3 , wherein the insoluble source of zinc ions comprises zinc oxide, zinc phosphate, zinc pyrophosphate or a mixture thereof. 
     
     
         8 . The composition of  claim 1  wherein the source of fluoride ions and the source of stannous ions comprises stannous fluoride. 
     
     
         9 . The composition of  claim 1  comprising at least one polyphosphate salt selected from the group consisting of inorganic polyphosphate salts which have equal to or less than three phosphorous atoms. 
     
     
         10 . The composition of  claim 6 , wherein the at least one polyphosphate is selected from the group consisting of tetrasodium pyrophosphate, sodium tripolyphosphate, and mixtures thereof; wherein the total polyphosphate comprises from 1 to 10 wt % of the composition 
     
     
         11 . The composition of  claim 1  wherein the buffering system comprises a mixture of citric acid and trisodium citrate. 
     
     
         12 . The composition of  claim 1  comprising polyvinylpyrrolidone, a gum, or a mixture thereof. 
     
     
         13 . The composition of  claim 1  comprising a modified cellulose such as carboxymethyl cellulose. 
     
     
         14 . The composition of  claim 1  further comprising at least one humectant selected from the group consisting of glycerin, polyethylene glycol, propylene glycol, and mixtures thereof. 
     
     
         15 . The composition of  claim 1  wherein the composition is a dentifrice comprising one or more of an abrasive, a surfactant, a foaming agent, a vitamin, a polymer, a whitening agent, an enzyme, a humectant, a thickener, an antimicrobial agent, a preservative, L-arginine, a flavoring, or a coloring agent. 
     
     
         16 . The composition of  claim 1  in a single phase. 
     
     
         17 . An oral care composition comprising:
 (a) 0.5-3 wt. % citric acid;   (b) 0.5-10 wt % Trisodium citrate;   (c) 0.1-5 wt % Zinc oxide;   (d) 0.1-5 wt % Stannous fluoride;   (e) 10-50 wt % Glycerin;   (f) 1-25 wt. % Propylene glycol;   optionally comprising one or more of:   (g) 0.1-12 wt % xanthan gum;   (h) 0.25-10 wt % polyvinylpyrrolidone (PVP);   (i) 0.2-1.5% wt. % carboxymethylcellulose (CMC);   (j) 5-60 wt % Silica (total);   (k) 0.1-10 wt % Tetrasodium Pyrophosphate (TSPP);   (l) 0- 5 wt % Sodium acid pyrophosphate (SAPP);   (m) 0.1-10 wt % Sodium Tripolyphosphate (STPP);   (n) 0.1-10 wt % Sodium lauryl sulfate (SLS);   (o) 0.1-10 wt % Cocamidopropyl betaine.   
     
     
         18 - 19 . (canceled) 
     
     
         20 . A method of treating or preventing a disease or condition of the oral cavity comprising contacting an oral cavity surface of a patient in need thereof with the composition of  claim 1  any one of the foregoing claims. 
     
     
         21 . The method of  claim 20 , wherein the disease or condition of the oral cavity is biofilm formation, plaque formation, oral inflammation or a combination thereof

Join the waitlist — get patent alerts

Track US2019133903A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.